Andy Judd

Company: Abbvie

Job title: Medicinal Chemist

Seminars:

Targeted Delivery of BCL-XL Selective Inhibitor Alleviates On-Target Toxicity of Systemically Dosed Inhibitors in Preclinical Models 9:00 am

Understanding how a pre-clinical mechanism-based cardiotoxicity of BCL-XL small molecule inhibitors led to the utilization of an antibody-targeted approach that has potential to differentiate from known platforms Reviewing the ADC approach manifested a novel BCL-XL toxicity in kidney Considering payload property modification contributed to establishing a TI suitable for clinical dosing Read more

day: Scientific Program Day Two